The Role of a Clinical Pharmacist in the Management of Type 2 Diabetic Patients in a Primary Medical Center in Jordan

Sponsor

University of Jordan (Other)

Overall Status

Completed

CT.gov ID

NCT06029842

Collaborator

(none)

103

Enrollment

Location

Arms

6.2

Actual Duration (Months)

16.6

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This study aimed to assess the impact of the clinical pharmacist on enhancing type 2 diabetic patients outcomes in a primary health care center.

Condition or Disease	Intervention/Treatment	Phase
Pharmacist-Patient Relations	Other: Collaborative approach of clinical pharmacist with physicians in a medical center	N/A

Detailed Description

About 103 patients with type 2 diabetes were randomized to control or intervention group, the control group received a standard care, while the intervention group received the collaborative care between the clinical pharmacist and physicians. Fasting blood glucose, HbA1c, Lipid profile, and blood pressure measured for both groups at baseline and after three months of follow-up. Treatment related problems (TRPs), quality of life, adherence, and patients knowledge about their medications were assessed. Cost avoidance and clinical significance of implemented clinical pharmacist interventions were assessed too.

Study Design

Study Type:

Interventional

Actual Enrollment :

103 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Triple (Participant, Care Provider, Outcomes Assessor)

Primary Purpose:

Other

Official Title:

A Randomized Controlled Trial to Assess the Role of a Clinical Pharmacist in the Management of Type 2 Diabetic Patients for Optimum Treatment Outcomes in a Primary Medical Center in Jordan

Actual Study Start Date :

Oct 17, 2022

Actual Primary Completion Date :

Apr 24, 2023

Actual Study Completion Date :

Apr 24, 2023

Arms and Interventions

Arm	Intervention/Treatment
Other: the intervention group this group received the collaborative care between the clinical pharmacist and physicians in a medical center	Other: Collaborative approach of clinical pharmacist with physicians in a medical center For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.
No Intervention: the control group this group received the standard care of physicians in a medical center without clinical pharmacist interventions

Arm

Intervention/Treatment

Other: the intervention group

this group received the collaborative care between the clinical pharmacist and physicians in a medical center

Other: Collaborative approach of clinical pharmacist with physicians in a medical center

For those who allocated to the intervention group, the clinical pharmacist interviewed them at each monthly visit about 30 minutes before seeing physicians, the clinical pharmacist identified treatment related problems, provided medication counseling, answered questions asked by patients or physicians, encouraged compliance, offered instructions on self-monitoring of blood pressure and glucose levels, distributed educational materials about diabetes and emphasis was made on optimizing adherence to pharmacological and non- pharmacological therapy. the pharmacist interventions on treatment related problems (TRPs) and proposed patient care plans were discussed with treatng physicians who decided to accept or reject them.

No Intervention: the control group

this group received the standard care of physicians in a medical center without clinical pharmacist interventions

Outcome Measures

Primary Outcome Measures

HbA1c [3 months]

Secondary Outcome Measures

Lipid profile [3 months]
LDL , HDL , TGS
Fasting blood glucose [each month for 3 months]
blood pressure [3 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

type 2 diabetic patients who aged 18 years or more with a HbA1c reading 6.5 % or more at the time of diagnosis

Exclusion Criteria:

pregnant patients
breastfeeding patients
patients with urgent or emergent cases
patients with cognitive impairment
if the patient is unable to provide informed written consent

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Abu-Nsair medical center	Amman		Jordan

Sponsors and Collaborators

University of Jordan

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Jyana Alelaimat, Master student at the University of Jordan, University of Jordan

ClinicalTrials.gov Identifier:

NCT06029842

Other Study ID Numbers:

Clinical pharmacist

First Posted:

Sep 8, 2023

Last Update Posted:

Sep 8, 2023

Last Verified:

Sep 1, 2023

Individual Participant Data (IPD) Sharing Statement:

Yes

Plan to Share IPD:

Yes

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Jyana Alelaimat, Master student at the University of Jordan, University of Jordan

clinical pharmacist

medical center

Ministry of Health

Collaborative approach

Study Results

No Results Posted as of Sep 8, 2023